Hong Kong Revises Medical Device Listing Guidance: What Manufacturers and Applicants Should Know

What Changed?

Hong Kong has updated two key guidance documents governing the listing of medical devices under its Medical Device Administrative Control System (MDACS).

On 31 July 2026, Hong Kong's Department of Health, through its Medical Device Division (MDD), updated:

• GN-02 — Guidance Notes for Listing Class II/III/IV General Medical Devices

• GN-06 — Guidance Notes for Listing Class B/C/D In Vitro Diagnostic (IVD) Medical Devices

The updated guidance took effect on the same date.

The two documents are particularly important for companies seeking to list higher-risk general medical devices and IVD medical devices in Hong Kong.

The MDD also clarified that medical-device listing applications already submitted through the Medical Device Information System (MDIS) are not affected by these updates, so applicants do not need to resubmit them.

Why Does This Matter?

Hong Kong currently operates the Medical Device Administrative Control System (MDACS) as its framework for the administrative control of medical devices.

Within this system, the MDD provides guidance covering areas such as device listing, conformity assessment, local responsible persons, importers, distributors and post-market activities. Its current issued-document library includes GN-02 for Class II/III/IV medical devices and GN-06 for Class B/C/D IVDs.

The latest update therefore matters to companies preparing or maintaining medical-device listing applications because the guidance used to support these applications has changed.

For manufacturers and their local partners, this reinforces an important regulatory principle:

A submission strategy needs to remain aligned with the regulator's current guidance, not simply the requirements that were in place when a previous application was prepared.

Who Should Pay Attention?

The update is particularly relevant to:

✔ Manufacturers of Class II, III and IV medical devices

✔ Manufacturers of Class B, C and D IVD medical devices

✔ Companies preparing new listing applications in Hong Kong

✔ Local Responsible Persons and regulatory representatives

✔ Regulatory affairs and quality teams

✔ International manufacturers planning entry into the Hong Kong market

Companies with existing applications or upcoming submissions should determine which version of the applicable guidance applies to their regulatory activities.

What Companies Should Do Next

1. Review the Updated GN-02 and GN-06

Companies preparing medical-device listing applications should review the latest versions of the applicable guidance rather than relying on older internal templates or submission checklists.

The MDD's current issued-document library identifies GN-02 and GN-06 as part of the active MDACS guidance framework.

2. Check Upcoming Submissions

If a company is preparing a new listing application after 31 July 2026, its regulatory team should ensure that the submission reflects the updated guidance.

This is particularly important for companies using previously prepared submission packages or documents developed for earlier applications.

3. Review Internal Regulatory Templates

Regulatory teams should consider updating internal checklists, submission templates, and document control procedures to reflect the latest guidance.

This can help prevent inconsistencies between internal regulatory processes and current MDD expectations.

4. Don't Assume Existing Applications Need to Be Resubmitted

The MDD has specifically clarified that listing applications already submitted through MDIS are not affected by the update and applicants do not need to resubmit them.

Companies should therefore distinguish between applications already submitted and new applications being prepared.

A Broader Regulatory Context

The latest update is part of an ongoing evolution of Hong Kong's medical-device regulatory framework.

The MDD has also updated other MDACS guidance during 2026. For example, GN-10, Guidance Notes for Changes of Listed Medical Devices, was updated with effect from 26 June 2026.

This illustrates why regulatory monitoring is increasingly important for manufacturers operating in Hong Kong.

Changes may not always take the form of an entirely new regulation. Updates to guidance documents can also affect how companies prepare, maintain or manage regulatory submissions.

ARQon Insight

For medical-device companies, regulatory intelligence is about more than identifying major legislative changes.

Guidance updates can be equally important because they influence how regulatory requirements are interpreted and applied in practice.

Hong Kong's latest update to GN-02 and GN-06 is a good example.

For companies entering or maintaining their presence in the Hong Kong market, regularly checking the latest MDD guidance can help regulatory teams identify changes early, update submission strategies, and avoid relying on outdated requirements.

The goal is not simply to respond when regulations change. It is to stay prepared for what changes next.

What This Means for Market Access

For international medical-device manufacturers, Hong Kong should be approached as a market requiring active regulatory monitoring.

Companies should consider:

Market entry → Device classification → Listing requirements → Supporting documentation → Local representation → Post-market compliance

Each stage can have regulatory implications, and changes to guidance can influence how companies approach their submissions.

The latest GN-02 and GN-06 updates therefore provide a timely reminder that maintaining market access requires continuous attention to the regulatory environment.

Key Takeaway

Hong Kong's Medical Device Division updated GN-02 and GN-06 on 31 July 2026, strengthening and updating the guidance used for listing Class II/III/IV general medical devices and Class B/C/D IVD medical devices under MDACS.

Importantly, applications already submitted through MDIS are not affected and do not need to be resubmitted.

For manufacturers and regulatory teams preparing future submissions, however, the update is a clear reminder to work from the latest regulatory guidance and keep internal submission processes aligned with current requirements.

How ARQon Can Support

ARQon supports healthcare and life-science companies with:

• Regulatory intelligence and monitoring

• Hong Kong market-entry strategy

• Medical-device regulatory support

• Regulatory gap analysis

• Submission planning

• Local market-access strategy

• Cross-border regulatory planning

Stay Ahead. Stay Compliant. Stay Informed.

With ARQon Regulatory Intelligence.